Methods and Resuls Forty rats were divided into four groups: (1) sham-operated rats without BQ123 administration, (2) rats with aortic banding without BQ123 administration, (3) sham-operated rats with BQ123 administration, and (4) rats with aortic banding with BQ123 administration. BQ123 (250 pug/h) was administered continuously by an osmotic pump starting 24 hours before operation. BQ123 blocked increases in the ratio of left ventricular weight to body weight and in the diameter of cardiomyocytes provoked by aortic banding at 1 week, but those blockade actions were no longer observed at 2 C ardiac hypertrophy provoked by mechanical stress, such as hemodynamic overload, results primarily from enlargement of cardiomyocytes rather than proliferation. During the development of experimental cardiac hypertrophy induced by workload, transcripts of several muscle-specific genes usually expressed by the embryonic and the fetal ventricle, for example, 3-myosin heavy chain, skeletal a-actin, and atrial natriuretic peptide (ANP),1 can be reexpressed. However, during the development of cardiac hypertrophy induced by neurohumoral factors, such as a,-adrenergic agonist,2'3 angiotensin II,4 and several growth factors,5'6 a subset of these muscle-specific genes can also be reactivated. Therefore, it appears that cardiac hypertrophy induced by mechanical overload and that induced by neurohumoral factors share signaling pathways in common.
Endothelin-1 (ET-1) is a 21-amino-acid residue vasoconstrictor peptide originally characterized from the supernatant of cultured porcine aortic endothelial cells.7 This endothelium-derived vasoconstrictive peptide has also been shown to be a potent growth factor in Received December 22, 1993 ; revision accepted February 7, 1994 .
From 
Experiment 2
For measurement of plasma ET-1 and ventricular ppET-1 mRNA levels, aortic banding and sham operation were performed in 39 rats in the same manner as in experiment 1. Six hours and 1, 2, and 4 days after operation (four or five rats per group), rats were anesthetized and blood samples were drawn from the right ventricle by cardiac puncture. After the rats were killed by exsanguination, LV free walls were excised and immediately frozen in liquid nitrogen. LV tissue specimens and blood samples from aortic-banded and sham-operated rats without BQ123 administration in experiment 1 were used for 1-week and 2-week measurements. Four rats without operation served as controls.
RNA Preparation and Analysis
Total RNA from LV free wall was isolated by guanidine thiocyanate and centrifuged through a 5.7 mol/L CsCl cushion.19 RNA was analyzed by Northern and dot blotting methods by hybridization to 32P-labeled cDNA probes prepared by the random-primer method20 in the same conditions as previously described. 10 At 1 week and 2 weeks after operation, aortic systolic pressure was elevated in the aortic banding groups. Administration of BQ123 did not affect aortic pressure in either sham-operated or aortic banding groups at 1 week and 2 weeks ( Table 1) .
The LV/body weight ratio significantly (P<.05) increased in rats with aortic banding at 1 week and 2 weeks after operation. Administration of BQ123 blocked the increased LV/body weight ratio provoked by load at 1 week, but the blockade action was no longer observed at 2 weeks (Table 1 ). The diameter of cardiomyocytes in the LV, as evaluated by morphometry, also increased in rats with aortic banding at 1 and 2 weeks after operation; however, increases in the cell diameter were not observed in rats with aortic banding plus BQ123 administration at 1 week. BQ123 did not inhibit increases in the diameter of cardiomyocytes in the LV at volved in the mechanism of cardiac hypertrophy provoked by hemodynamic overload in vivo. Rats with LV overload produced by aortic banding are widely used as an in vivo experimental model for cardiac hypertrophy. During the course of LV hypertrophy, several genes encoding contractile protein isoforms ordinarily expressed in the embryonic or fetal ventricle are reactivated. In this study, we used skeletal a-actin and ANP mRNA as markers for cardiac hypertrophy, because these genes are in vivo correlates for the changes seen with hypertrophy stimulated by neurohumoral factors in vitro. The present study clearly shows the blockade actions by BQ123 on skeletal a-actin and ANP mRNA levels in the rats with aortic banding at 1 week. Taken together with the present data that BQ123 inhibited the ratio of LV weight to body weight and diameter of cardiomyocytes in the LV, our results are in accord with the hypothesis that endogenous ET-l may play a role in the mechanism of cardiac hypertrophy provoked by hemodynamic overload. The specificity of BQ123 on ETA receptor antagonistic action has been well examined in vivo24 as well as in vitro25; therefore, it is unlikely that the inhibitory action of BQ123 on cardiac hypertrophy may be mediated by other neurohumoral factors, such as a,-adrenergic stimulator and angiotensin II. Since BQ123 did not affect aortic pressure in rats with aortic banding or sham operation, the inhibitory effect of BQ123 on cardiac hypertrophy was not due to its direct action on blood pressure. In the present study, we also demonstrated that both ppET-1 mRNA in LV and plasma ET-1 levels were transiently increased after aortic banding, suggesting the local production of ET-l in the cardiovascular system during the early course of cardiac hypertrophy.
Several neurohumoral and growth factors, such as a1-adrenergic agonists,2,3 angiotensin II,4 basic fibroblast growth factor, and insulin-like growth factor-I,6 have been reported to induce cardiomyocyte hypertrophy in vitro. However, the contribution of such factors, except for angiotensin II,26 to cardiac hypertrophy induced by mechanical overload in vivo has not been proved. Thus, our study is the first report that clearly shows the causal relation of endogenous ET-1 to pressure-induced cardiac hypertrophy in vivo. The continuous infusion of BQ123 (250 1tg/h) used in this study maintains its plasma levels at almost 5x1O`mol/L; these concentrations were comparable to those that inhibit the cardiac hypertrophy action by angiotensin II in vitro.12 It should be noted that blockade effects by BQ123 on cardiac hypertrophy and ventricular skeletal a-actin and ANP gene expression were no longer observed at 2 weeks after aortic banding. Since ETA receptor and its mRNA are not upregulated during cardiomyocyte hypertrophy in vitro,27 it is unlikely that the inability of BQ123 to maintain an inhibitory effect is due to the compensatory upregulation of ETA receptor on cardiomyocytes. Therefore, it is possible to speculate that cardiac ET-1 may act as an "initiating" hypertrophy factor during the early phase of pressure overload but that other factors, such as local renin-angiotensin systems and several growth factors, might take over as a "maintaining" factor during the late phase of pressure overload.
The clinical application of ETA receptor antagonists to prevention and treatment of cardiac hypertrophy might be limited because of its short half-life in circulation and its route of administration. Nevertheless, our present results provide a possible therapeutic approach using ET receptor antagonist for cardiac hypertrophy by blockade of endogenous ET-1.
